PH-sensitive pullulan-based nanoparticle carrier of methotrexate and combretastatin A4 for the combination therapy against hepatocellular carcinoma

Biomaterials

Volumn 34, Issue 29, 2013, Pages 7181-7190

  Wang, Yinsong ^a   Chen, Hongli ^b   Liu, Yuanyuan ^a   Wu, Jing ^a   Zhou, Ping ^a   Wang, Yan ^a   Li, Rongshan ^a   Yang, Xiaoying ^a   Zhang, Ning ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

Combination therapy; Nanoparticle carrier; Pullulan; Targeting

Indexed keywords

COMBINATION THERAPY; DEGREE OF SUBSTITUTION; DRUG CARRIER SYSTEMS; HEPATOCELLULAR CARCINOMA; INTRAVENOUS INJECTIONS; METHOTREXATE (MTX); PULLULANS; TARGETING;

DRUG THERAPY;

NANOPARTICLES;

COMBRETASTATIN A4; METHOTREXATE; N UROCANYL PULLULAN; NANOCARRIER; PULLULAN; UNCLASSIFIED DRUG; UROCANIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CELL STRAIN HEPG2; CONTROLLED STUDY; DIALYSIS; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG LIVER LEVEL; DRUG RELEASE; DRUG TARGETING; DRUG TUMOR LEVEL; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; MOUSE; NANOFABRICATION; NONHUMAN; PARTICLE SIZE; PH; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DELAYED-ACTION PREPARATIONS; GLUCANS; HEP G2 CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; LIVER; LIVER NEOPLASMS; METHOTREXATE; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, MOLECULAR; NANOPARTICLES; STILBENES;

MUS MUSCULUS;

EID: 84879600243     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.05.081     Document Type: Article

References (44)

1. El-Serag H.B., Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. NEngl J Med 1999, 340:745-750.
2. Montesano R., Hainaut P., Wild C.P. Hepatocellular carcinoma: from gene to public health. JNatl Cancer Inst 1997, 89:1844-1851.
3. Bruix J., Sherman M., Llovet J.M., Beaugrand M., Lencioni R., Burroughs A.K., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. JHepatol 2001, 35:421-430.
4. Llovet J.M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37:429-442.
5. Zetter B.R. Angiogenesis and tumor metastasis. Annu Rev Med 1998, 49:407-424.
6. Semela D., Dufour J.F. Angiogenesis and hepatocellular carcinoma. JHepatol 2004, 41:864-880.
7. Ker C.G., Chen H.Y., Juan C.C., Lo H.W., Shen Y.Y., Chen J.S., et al. Role of angiogenesis in hepatitis and hepatocellular carcinoma. Hepatogastroenterology 1999, 46:646-650.
8. Pang R., Poon R.T. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett 2006, 242:151-167.
9. Kerbel R.S. Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. JClin Oncol 2001, 19:45S-51S.
10. Ma J., Waxman D.J. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 2008, 7:3670-3684.
11. Huber P.E., Bischof M., Jenne J., Heiland S., Peschke P., Saffrich R., et al. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res 2005, 65:3643-3655.
12. Blagosklonny M.V. Antiangiogenic therapy and tumor progression. Cancer Cell 2004, 5:13-17.
13. Huang G.W., Yang L.Y., Lu W.Q. Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: impact on neovascularization and survival. World J Gastroenterol 2005, 11:1705-1708.
14. Zhu H., Chen X.P., Luo S.F., Guan J., Zhang W.G., Zhang B.X. Involvement of hypoxia-inducible factor-1-alpha in multidrug resistance induced by hypoxia in HepG2 cells. JExp Clin Cancer Res 2005, 24:565-574.
15. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001, 7:987-989.
16. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
17. Goel S., Duda D.G., Xu L., Munn L.L., Boucher Y., Fukumura D., et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011, 91:1071-1121.
18. Cairns R., Papandreou I., Denko N. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res 2006, 4:61-70.
19. Cerniglia G.J., Pore N., Tsai J.H., Schultz S., Mick R., Choe R., et al. Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy. PLoS One 2009, 4:e6539.
20. Sengupta S., Eavarone D., Capila I., Zhao G., Watson N., Kiziltepe T., et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005, 436:568-572.
21. Yang T., Wang Y., Li Z., Dai W., Yin J., Liang L., et al. Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature. Nanomedicine 2012, 8:81-92.
22. Kaneo Y., Tanaka T., Nakano T., Yamaguchi Y. Evidence for receptor-mediated hepatic uptake of pullulan in rats. JControl Release 2001, 70:365-373.
23. Tanaka T., Hamano S., Fujishima Y., Kaneo Y. Uptake of pullulan in cultured rat liver parenchymal cells. Biol Pharm Bull 2005, 28:560-562.
24. Jo J., Yamamoto M., Matsumoto K., Nakamura T., Tabata Y. Liver targeting of plasmid DNA with a cationized pullulan for tumor suppression. JNanosci Nanotechnol 2006, 6:2853-2859.
25. Kang J.H., Tachibana Y., Kamata W., Mahara A., Harada-Shiba M., Yamaoka T. Liver-targeted siRNA delivery by polyethylenimine (PEI)-pullulan carrier. Bioorg Med Chem 2010, 18:3946-3950.
26. Suginoshita Y., Tabata Y., Matsumura T., Toda Y., Nabeshima M., Moriyasu F., et al. Liver targeting of human interferon-beta with pullulan based on metal coordination. JControl Release 2002, 83:75-88.
27. Suginoshita Y., Tabata Y., Moriyasu F., Ikada Y., Chiba T. Liver targeting of interferon-beta with a liver-affinity polysaccharide based on metal coordination in mice. JPharmacol Exp Ther 2001, 298:805-811.
28. Tabata Y., Matsui Y., Uno K., Sokawa Y., Ikada Y. Simple mixing of IFN with a polysaccharide having high liver affinity enables IFN to target to the liver. JInterferon Cytokine Res 1999, 19:287-292.
29. Xi K., Tabata Y., Uno K., Yoshimoto M., Kishida T., Sokawa Y., et al. Liver targeting of interferon through pullulan conjugation. Pharm Res 1996, 13:1846-1850.
30. Lin C.M., Ho H.H., Pettit G.R., Hamel E. Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry 1989, 28:6984-6991.
31. Jin H., Xu C.X., Kim H.W., Chung Y.S., Shin J.Y., Chang S.H., et al. Urocanic acid-modified chitosan-mediated PTEN delivery via aerosol suppressed lung tumorigenesis in K-ras(LA1) mice. Cancer Gene Ther 2008, 15:275-283.
32. Kim T.H., Ihm J.E., Choi Y.J., Nah J.W., Cho C.S. Efficient gene delivery by urocanic acid-modified chitosan. JControl Release 2003, 93:389-402.
33. Wang W., Yao J., Zhou J.P., Lu Y., Wang Y., Tao L., et al. Urocanic acid-modified chitosan-mediated p53 gene delivery inducing apoptosis of human hepatocellular carcinoma cell line HepG2 is involved in its antitumor effect invitro and invivo. Biochem Biophys Res Commun 2008, 377:567-572.
34. DeLisser H.M., Christofidou-Solomidou M., Strieter R.M., Burdick M.D., Robinson C.S., Wexler R.S., et al. Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol 1997, 151:671-677.
35. Weidner N., Semple J.P., Welch W.R., Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. NEngl J Med 1991, 324:1-8.
36. Sanchez-Camazano M., Sanchez-Martin M.J., Rodriguez-Cruz M.S. Sodium dodecyl sulphate-enhanced desorption of atrazine: effect of surfactant concentration and of organic matter content of soils. Chemosphere 2000, 41:1301-1305.
37. Kim Y.H., Gihm S.H., Park C.R., Lee K.Y., Kim T.W., Kwon I.C., et al. Structural characteristics of size-controlled self-aggregates of deoxycholic acid-modified chitosan and their application as a DNA delivery carrier. Bioconjug Chem 2001, 12:932-938.
38. Henni W., Deyme M., Stchakovsky M., LeCerf D., Picton L., Rosilio V. Aggregation of hydrophobically modified polysaccharides in solution and at the air-water interface. JColloid Interface Sci 2005, 281:316-324.
39. Wang Y.S., Jiang Q., Li R.S., Liu L.L., Zhang Q.Q., Wang Y.M., et al. Self-assembled nanoparticles of cholesterol-modified O-carboxymethyl chitosan as a novel carrier for paclitaxel. Nanotechnology 2008, 19:145101.
40. Li S.D., Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008, 5(4):496-504.
41. Alexis F., Pridgen E., Molnar L.K., Farokhzad O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008, 5:505-515.
42. Tang H.B., Li L., Chen H., Zhou Z.M., Chen H.L., Li X.M., et al. Stability and invivo evaluation of pullulan acetate as a drug nanocarrier. Drug Deliv 2010, 17:552-558.
43. Ayame H., Morimoto N., Akiyoshi K. Self-assembled cationic nanogels for intracellular protein delivery. Bioconjug Chem 2008, 19:882-890.
44. Zhang H.Z., Gao F.P., Liu L.R., Li X.M., Zhou Z.M., Yang X.D., et al. Pullulan acetate nanoparticles prepared by solvent diffusion method for epirubicin chemotherapy. Colloids Surf B Biointerfaces 2009, 71:19-26.